about
Metformin in breast cancer: time for actionQuality of life in a randomized trial of group psychosocial support in metastatic breast cancer: overall effects of the intervention and an exploration of missing data.Polymorphisms cMyc-N11S and p27-V109G and breast cancer risk and prognosis.Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.Obesity and Cancer: Insights for Clinicians.Understanding the benefit of metformin use in cancer treatment.Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: results from the Breast Cancer Family Registry.Health-related quality-of-life measurement in randomized clinical trials in breast cancer--taking stock.Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study.Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32.25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1The role of obesity in cancer survival and recurrence.Economic issues in lung cancer.Support groups in advanced breast cancer.Second consensus on medical treatment of metastatic breast cancer.Past, present, and future challenges in breast cancer treatment.Health-related quality of life measurement in symptom management trials.Physical activity, weight control, and breast cancer risk and survival: clinical trial rationale and design considerations.Association between metformin therapy and mortality after breast cancer: a population-based study.Family history of breast cancer and all-cause mortality after breast cancer diagnosis in the Breast Cancer Family Registry.Prediagnosis reproductive factors and all-cause mortality for women with breast cancer in the breast cancer family registry.Prognosis of BRCA-associated breast cancer: a summary of evidence.Commentary on: "Effect of obesity on survival in women with breast cancer: systematic review and meta-analysis" (Melinda Protani, Michael Coory, Jennifer H. Martin).Body size and breast cancer prognosis: a critical review of the evidence.Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009).Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin.Second malignant neoplasms: assessment and strategies for risk reduction.Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and meta-analysis.Impact of the obesity epidemic on cancer.Recommendations for Obesity Clinical Trials in Cancer Survivors: American Society of Clinical Oncology Statement.Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome.Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities.Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer.Three methods for minimally important difference: no relationship was found with the net proportion of patients improving.Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32.Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls.Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study.Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial.Obesity, insulin resistance and breast cancer outcomes.
P50
Q28247070-C862F5FF-216D-4B8B-9B54-A6974805DE12Q30792749-343FE981-F680-427C-9799-2951C23DAE87Q33287624-A8AE2029-6ACB-451B-8A60-F2FDA742BEC6Q33718914-DD904B4D-CF78-4AE7-8532-B055D72EA2C3Q33756434-B1F3DB4F-9E1D-4A67-B6E0-A606F6AF6B42Q33864199-77B76813-8AF4-4755-B3A8-4704A376029FQ34061135-EF7E9700-B59D-455D-A68E-7C25FD8ECEDFQ35068200-1FCE2150-499D-47C2-8922-AA51B96CF90DQ35238162-AFCACCC7-9812-4EAD-8CBC-872F6D91D922Q36047450-1EC0E903-0B52-48B7-9D07-65E0A42BF9CEQ36093774-8ED389E1-F0B3-4A7D-A121-30519B5C91F4Q36152955-38D3A4A6-D145-450F-A972-59C21A0602D0Q36223126-0E110C7D-5B8B-4CC1-8225-96ECA57DA248Q36296321-27699908-A1D4-4F88-9D12-DF56050D0B04Q36532480-ED9DBF60-144E-418B-833B-F38427CB823FQ36934273-B9162554-BC7F-4840-A22B-CD25A67E65E9Q36977018-11978B6B-7505-49B2-9836-72FA7DC25268Q37180714-17F913F0-2889-4A90-8AF7-C57BFA4EFB66Q37193432-36B2669E-F8C0-4639-8425-E48BAC660514Q37308563-9BBE0DC5-2DAC-4EFD-8A1E-42C7EF66010FQ37353677-337473A4-0CB9-4E2C-BF93-B756D8E2B801Q37605624-C89CF772-79BA-497E-BCB5-821DA2BC94A5Q37780117-177A5AE2-69E4-479B-AD23-648BD366BBB7Q37790609-19386AFE-FAFD-4FD0-A224-9828770E7654Q37803154-E8B533AB-B764-4259-A437-8938B76A234BQ37827010-9EA649A0-8770-4AB8-81A3-9014879F1852Q37947906-65A50FB2-1CE7-41C4-8B72-401413714E3DQ38046164-6DE3338E-39EB-4D5A-A87D-25F83287E771Q38150669-C6A541D7-B712-4AAA-9C02-22338CB6FB97Q38271295-63E3BDD2-0BF0-4D16-A647-8F84578442FDQ38577722-B857E7F5-CE64-4830-A1C0-8024338E468AQ39024746-92D6C38B-12F3-48C9-90CD-DB5F70BE624DQ39024751-26C287E5-D582-4226-A434-6169716A64D6Q40042128-20338904-B454-40E2-B907-F407DA94F324Q40225077-3E7F8B2B-2B65-408C-9FB6-2216584E4E11Q40225979-AEEDF542-B580-44D5-B28B-672A3413E770Q40227381-ABB3BA6A-8ECB-4F4B-BDFA-5CF268F55CB4Q40376070-12BAB27E-8827-44F9-BE00-9A4A9C4F44C0Q41435904-7AA53A66-9876-4F72-AD9A-B5241F77CF35Q41474276-4C2D9FE5-6C9C-421B-81EC-0590E428D2DE
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Pamela J Goodwin
@ast
Pamela J Goodwin
@en
Pamela J Goodwin
@es
Pamela J Goodwin
@nl
Pamela J Goodwin
@sl
type
label
Pamela J Goodwin
@ast
Pamela J Goodwin
@en
Pamela J Goodwin
@es
Pamela J Goodwin
@nl
Pamela J Goodwin
@sl
prefLabel
Pamela J Goodwin
@ast
Pamela J Goodwin
@en
Pamela J Goodwin
@es
Pamela J Goodwin
@nl
Pamela J Goodwin
@sl
P106
P21
P31
P496
0000-0003-2637-6906